This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	VEGF receptor 2 (KDR/Flk-1; VEGFR-2)	Studies in mice suggest that T cells engineered to target VEGFR-2 could help treat metastatic cancer. In mice, i.v. infusion of T cells engineered to express an antibody fragment against VEGFR-2 decreased tumor growth and increased survival compared with infusion of control T cells. Next steps include a Phase I/II dose-escalation trial to treat metastatic cancer. At least 16 companies have VEGFR-2 inhibitors in development stages ranging from preclinical to marketed to treat cancer. SciBX 3(42); doi:10.1038/scibx.2010.1261 Published online Oct. 28, 2010	Patent application filed; available for licensing	Chinnasamy, D. <i>et al. J. Clin. Invest.</i>; published online Oct. 11, 2010; doi:10.1172/JCI43490 Contact: Steven A. Rosenberg, National Cancer Institute, Bethesda, Md. e-mail: SAR@mail.nih.gov